Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning.
Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning.
复制标题
DOI：
10.1016/s0936-6555(05)80549-7
复制
发表时间：
1995-01-01
期刊：
影响因子：
--
通讯作者：
Carr, R
中科院分区：
文献类型：
--
作者：
Barrington, S F;Carr, R
正电子发射断层扫描 (PET) 是一种使用生物示踪剂（18-氟氟脱氧葡萄糖 (FDG)）的成像技术，肿瘤细胞对生物示踪剂的摄取增加。先前在淋巴瘤患者中进行的研究表明，PET 是一种准确的疾病分期方法，并且治疗前 FDG 的高摄取（在化疗结束时消失）与良好的临床反应相关。本病例报告表明，临床 PET 扫描对于对广泛结外和骨髓受累的淋巴瘤患者进行分期特别有用，并且 PET 可以在很短的时间内跟踪肿瘤活力的变化。
Positron emission tomography (PET) is an imaging technique using biological tracers (18-fluorine fluorodeoxyglucose (FDG)), whose uptake into tumour cells is increased. Previous studies carried out in patients with lymphoma have shown that PET is an accurate method of staging disease and that a high pre-treatment FDG uptake that is abolished by the end of chemotherapy is associated with a good clinical response. This case report demonstrates that clinical PET scanning can be especially useful in staging patients with lymphoma in whom there is extensive extranodal and marrow involvement, and that PET can follow changes in tumour viability over a very short time span.